Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

@article{Peethambaram1999RandomizedTO,
  title={Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis},
  author={Prema P. Peethambaram and James N. Ingle and Vera J. Suman and Lynn C. Hartmann and Charles L Loprinzi},
  journal={Breast Cancer Research and Treatment},
  year={1999},
  volume={54},
  pages={117-122}
}
One hundred fifty‐one postmenopausal women with progressive metastatic breast cancer and no prior hormonal therapy were treated with either diethylstilbestrol (DES) or tamoxifen (TAM). One hundred forty‐three eligible patients were followed until death or for a minimum of 14.1 years on the DES arm or 16.7 years on the TAM arm. The overall objective response was 42% for DES and 33% for TAM (p=0.31) and the median duration of response was 11.8 months for DES and 9.9 months for TAM (p=0.38… CONTINUE READING